A COMPARITIVE STUDY OF EFFICACY AND SAFETY OF INTRAVENOUS IRON SUCROSE VS INTRAVENOUS FERRIC CARBOXY MALTOSE IN CORRECTING IRON DEFICIENCY ANAEMIA IN POST PARTUM PERIOD

Dr. Anukrati Singh; Dr. Poonam Singh; Dr. Shubhra Agarwal

Volume : IX, Issue : II, February - 2020

A COMPARITIVE STUDY OF EFFICACY AND SAFETY OF INTRAVENOUS IRON SUCROSE VS INTRAVENOUS FERRIC CARBOXY MALTOSE IN CORRECTING IRON DEFICIENCY ANAEMIA IN POST PARTUM PERIOD

Dr. Anukrati Singh, Dr. Poonam Singh, Dr. Shubhra Agarwal

Abstract :

INTRODUCTION: Post partum anemia needs a major concern not only to ensure healthy puerperum, better mother baby bonding, build up iron reserves in the puerpurae to have a better quality of life and also to ensure minimized incidence of anemia in next pregnancy and to crucially avoid maternal and perinatal mortalities. This co–morbid condition can be effectively treated with the help of intravenous iron therapy. This study aims to compare the efficacy and safety of intravenous ferric carboxymaltose with intravenous iron sucrose in treating anemia during post–partum period. METHOD: This interventional prospective study conducted in the Department of Obstetrics and Gynecology at T.M.U Moradabad, India, encompassed a total of 120 postnatal women in the 2 equal predefined study group, pertaining to– Group A who received intravenous iron sucrose and Group B who received intravenous ferric carboxymaltose. The rise in Hemoglobin and serum ferritin levels and with the evaluation of its safety and tolerance were compared primarily at 24hr postpartum and secondarily at 3weeks post treatment amongst the two groups. RESULTS: The mean rise in the hemoglobin level with ferric carboxymaltose was 2.35 gm/dl and with that of iron, sucrose was 1.51 gm/dl(p value <.01). The mean rise in the serum ferritin levels with ferric carboxymaltose was 53.03ng/ml and with iron sucrose was 43.91 ng/ml.(p value < .01). Ferric carboxymaltose was observed to be safer with less adverse events in comparison to the Iron sucrose. CONCLUSION: Properties like ultra–short duration of treatment, fewer adverse reactions and better compliance makes FCM the first–line drug in the management of postpartum iron deficiency anemia.